The Keri Lab has a record of publishing research in high-impact peer-reviewed journals. Below are the most 5 recent publications from our lab. The National Center for Biotechnology Information contains an up-to-date list of all of our publications.
A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis. Anstine LJ, Keri RA. J Cancer Metastasis Treat. 2019 Jun 13. doi: 10.20517/2394-4722.2019.24.
The Activin Social Network: Activin, Inhibin and Follistatin in Breast Development and Cancer. Seachrist DD, Keri RA. Endocrinology. 2019 Mar 15; 160(5):1097-1110. doi: 10.1210/en.2019-00015.
Targeting BCL-xL improves the efficacy of bromodomain and extra-terminal protein inhibitors in triple-negative breast cancer by eliciting the death of senescent cells. Gayle SS, Sahni JM, Webb BM, Weber-Bonk KL, Shively MS, Spina R, Bar EE, Summers MK, Keri RA. J Biol Chem. 2018 Nov 27. doi: 10.1074/jbc.RA118.004712.
Targeting bromodomain and extraterminal proteins in breast cancer. Sahni JM, Keri RA. Pharmacol Res. 2018 Mar; 129:156-176. doi: 10.1016/j.phrs.2017.11.015.
Mitotic Vulnerability in Triple-Negative Breast Cancer Associated with LIN9 is Targetable with BET Inhibitors. Sahni JM, Gayle SS, Webb BM, Weber-Bonk KL, Seachrist DD, Singh S, Sizemore ST, Restrepo NA, Bebek G, Scacheri PC, Varadan V, Summers MK, Keri RA. Cancer Res. 2017 Oct 1; 77(19):5395-5408. doi: 10.1158/0008-5472.CAN-17-1571.